For providers
Transform the future of cancer screening with the Cancerguard™ test
One simple blood draw can help you detect cancer earlier and impact more lives.1
For adults 50-84, with no cancer in the last 3 years1
Helps detect cancers responsible for at least 80% of diagnoses2
Helps detect aggressive cancers, including 6 of the most deadly*,†,2
$689, HSA/FSA eligible‡
With ~600,000 deaths in the
US every year, cancer is the
2nd deadliest disease4
Recommended screening only catches 1 in 7 cancers§,5
Only 4 types of cancer have recommended screening options3
The Cancerguard test dramatically expands your screening power
The Cancerguard test
Helps find the deadliest cancers
Cancerguard showed a 68% sensitivity for the most deadly cancers with the lowest 5-year survival rates like pancreatic, lung, liver, esophageal, stomach, and ovarian cancers. It can offer clear, life-changing insights earlier, when treatment can make the biggest difference.2
Helps find cancers behind at least 80% of diagnoses2
Cancerguard screens for cancer types responsible for the majority of annual cancer diagnoses in the U.S. including the ones that are hardest to find.
With Cancerguard, you can expand your screening capabilities to enable more comprehensive proactive care.
Detected more than 1 in 3 early stage cancers2
Catching cancer earlier can change everything. The Cancerguard test found 1 in 3 early-stage cancers in a study.
You can help your patients move forward with confidence--and stay one step ahead of even the most aggressive cancers.
97.4% specificity may limit false positives2
With high specificity, the Cancerguard test delivers actionable results.
Low false positive rates, which minimize unnecessary imaging and follow up, mean you can do more for your patients.
Designed for precision
Multiple biomarker classes. Actionable results.
The only test of its kind to combine DNA methylation and protein biomarkers2
- Analyzing multiple biological signals casts a wider net for detecting cancer in its early stages.
- Our multi-biomarker class approach boosts detection of 6 of the deadliest cancer* organ types with the shortest 5-year survival rate.
- This means the Cancerguard test has high sensitivity and can detect signals across 20 cancer types.
Designed to minimize unnecessary follow-ups
Cancerguard was designed to streamline the diagnostic workflow after a patient receives a positive result.
Expert-designed imaging workflow
Developed by radiologists and health system experts to ease implementation
Less guesswork. Greater efficiency.
An imaging-based diagnostic workflow designed to help you provide consistent, reliable follow-up care for patients
Showed a ~30% reduction in diagnostic burden
Fewer procedures vs. molecular methods on modeling outcomes6
Imaging resolution workflow is based on published expert clinician opinion and results from an exploratory, prospective, interventional modeling study. It is not a replacement for clinical standard of care. There are no established guidelines for imaging following a positive Cancerguard test result. Providers should use their clinical judgement and experience when deciding how to diagnose or treat patients.
Trusted guidance to ease patient anxiety
When patients test positive, we're here to help them. Our Positive Results Services provide patients with hands-on guidance for their next steps.
Patient Care Navigation
Our Care Navigators can act as a patient’s personal guide after a positive test result and cover things like:
- Finding locations for follow-up imaging and testing
- Providing eligibility details for our Patient Imaging Reimbursement Program
- Help assess and reduce barriers to getting follow-up care
Imaging Reimbursement Program
If a patient has a positive test result, we offer an imaging reimbursement program for eligible patients to help reduce costs, so they can stay focused on their health with your guidance. Coverage varies based on insurance plans and a patient's unique situation, and doesn't include covered imaging costs, including copay, coinsurance, and/or deductible amounts.
The Imaging Reimbursement program will not reimburse any covered imaging costs, including copay, coinsurance and/or deductible amounts determined by insurance.
Results designed for clarity.
Patients results are ready about 2 weeks after our lab receives their blood sample. Results are either positive or negative and can help you determine next steps. In rare cases, an invalid result can occur.6
Negative Result
A negative result means the test did not find signals of cancer.6
Your patient can continue with their recommended cancer screening schedule and standard of care.
Positive Result
A positive result means the test found a signal that may indicate the presence of cancer. It’s not a cancer diagnosis.7
Follow-up imaging and further evaluation are needed to locate and confirm a diagnosis, or determine that cancer is not present.8
*False negative and false positive results can occur. A false negative result means the test did not find signals of cancer, but a person does have cancer. A false positive result means the test found signals of cancer, but a person doesn’t have cancer.
Trust a leader in cancer diagnostics
With over two decades of experience helping millions navigate life-changing cancer diagnoses, Exact Sciences is redefining cancer screening with Multi-Cancer Early Detection (MCED) testing.9
Partnering with the brightest minds in cancer research
Exact Sciences has been leading the development of MCED testing in collaboration with the broader cancer community. We work with patient advocacy groups, forums, and researchers at premier institutions to help to shape the future of cancer detection.10
Get started today
The Cancerguard test is intended for people aged 50-84 with no cancer diagnosis in the last 3 years.1
Three ways to use DNA to gain insight
Cancerguard is one of three distinct tests we offer that look for cancer in different ways. Here’s what sets them apart.
Screening
Multi-Cancer Early Detection (MCED) test
MCED tests like the Cancerguard test help detect hard-to-find cancers and in earlier stages when they are more treatable.
Risk Detection
Hereditary Cancer Test
(HCT)
Tests like Riskguard® can help uncover hereditary cancer risk. It checks for genetic changes from your family line that can cause an increased risk for certain cancers.
Monitoring
Molecular Residual Disease (MRD) test
MRD tests like Oncodetect™ are tumor-informed tests that can detect circulating tumor DNA in the blood during or after cancer treatment.
Have questions?
Call us at 844-870-8870 .
Footnotes and references
- pancreatic, esophageal, liver, lung, stomach, ovarian
- American Cancer Society. Cancer Facts & Figures 2025. Cancer.org. Published 2025.
- $689 amount reflects self-pay price. FSA/HSA/HRA programs may be a resource you could use to pay as well.
- Limitations: Based on modeling data derived from numerous sources including self-reported surveys. Includes assumptions on detectability of certain cancer types. Does not include all cancer types or screening methods.
- Exact Sciences. Exact Sciences Specimen Collection Guide Preparation Collection and Processing. Published 2024, Accessed June 13, 2025
- Data on file. Cancerguard Test development study. 2025. Bioinformatics, Exact Sciences, Madison, WI
- Data on file. Calculated cancers without USPSTF recommended screening tests. 2025.
- Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer. J Clin. 2025;75(1):10‐45.
- NORC at the University of Chicago. Percent of Cancers Detected by Screening in the U.S. Published 2022. Accessed June 13, 2025
- Exact Sciences. Cancerguard™ Patient Support Guide. Published 2025 Accessed July 11, 2025.
- Exact Sciences. Patient Positive Result Supplement. Published 2025. Accessed July 11 2025
- Exact Sciences. Cancerguard™ Care Navigation Guide. Published 2025. Accessed July 23, 2025.
- Exact Sciences. Exact Sciences Company History. Published 2025. Accessed June 13, 2025
- Choudhry O, Kharge A, Rego S, et al. DETECT-A Participants with Pre-Malignant Conditions Diagnosed Consequent to an MCED Test.; 2024. Accessed June 13, 2025.